SHANGHAI, Dec. 5, 2025 /PRNewswire/ -- A clinical study developed by Professor Gang Shen's Orthodontic Team from Taikang Bybo Dental has been officially published in the Journal of Aligner Orthodontics (JAO). The article presents key findings on the use of Mandibular Advancement Repositioning Therapy (MART) implemented through the S8-SGTB, a clear orthodontic appliance jointly developed by Smartee Denti-Technology and Prof. Gang Shen's team. The insight of the report expands non-surgical treatme

Dive Brief:Biotechnology company Tr1x on Wednesday became the latest startup to raise tens of millions of dollars in venture funding to develop a new type of cell therapy for autoimmune conditions.The San Diego-based startup launched with $75 million and plans to advance a pipeline of regulatory T cell, or Treg, therapies for graft-versus-host disease, inflammatory bowel disease and other disorders. It plans to begin multiple clinical trials later this year, according to a statement.Tr1x is led

Tr1X debuted Wednesday with a $75 million series A and a plan to engineer donor T cells into a Treg subtype lookalike that could yield anti-inflammatory and targeted cell therapies for autoimmune diseases.The round will enable Tr1X to bring its lead candidate, TRX103, into the clinic this year to prevent Graft versus Host Disease (GvHD) in patients undergoing mismatched hematopoietic stem cell transplant. The company also has preclinical programmes for inflammatory bowel disease, Type 1 diabetes

Halozyme said a German court has blocked Merck from selling a subcutaneous version of Keytruda in the country. The decision marks an advance for Halozyme, which is in a broader patent dispute with Merck centered on its drug delivery technology. When Merck developed subcutaneous Keytruda, it tweaked a key enzyme, called PH20, in certain ways. Halozyme believes other companies can’t make those specific tweaks because patents protect its MDASE delivery technology. Merck has denied this claim, maint

Tr1x launched from stealth Wednesday with $75 million to tackle graft-versus-host disease in addition to inflammatory and autoimmune conditions. The biotech was created by Maria Grazia Roncarolo, the Stanford Medicine scientist who co-founded Graphite Bio and Kamau Therapeutics. Bill Lis, who previously led Jasper Therapeutics and Portola Pharmaceuticals, is Tr1x’s CEO. Roncarolo’s team was the first to discover a type of immune cell called type 1 regulatory T cells — or Tr1 cells — the namesake

SAN DIEGO, CA, USA I January 17, 2024 I Tr1X, Inc. today announced its emergence from stealth with a $75 million Series A financing to bring universal allogeneic regulatory T (Treg) and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases. The financing was led by Bay Area-based The Column Group, with participation from NEVA SGR and Alexandria Ventures. The Company appointed William Lis Chief Executive Officer, strengthened its leadership team

When immune cells go awry and spark inflammation, a different type of immune cell stands ready to counteract that effect and return the immune system to a state of balance. Therapies based on such cells are part of an emerging area of research for the treatment of a wide range of autoimmune diseases. The work of Tr1X focuses on a particular type of these cells and the startup has emerged from stealth with $75 million and a lead program on track for the clinic later this year. The cells that tamp

3d render of cytotoxic CAR exosomes secreted by engineered T immune cells Meletios Verras/Getty Images/iStockphoto The San Diego-based startup, specializing in allogeneic engineered Treg and CAR-Treg cell therapies, plans to be in Phase I clinical trials in multiple indications in 2024. Pictured: Cell therapy concept/iStock, Meletios Verras Tr1X came out of stealth mode on Wednesday with $75 million in Series A funding as it looks to bring allogeneic engineered Treg and CAR-Treg cell therapie

Pictured: Cell therapy concept/iStock, Meletios Verras Tr1X came out of stealth mode on Wednesday with $75 million in Series A funding as it looks to bring allogeneic engineered Treg and CAR-Treg cell therapies to treat major autoimmune diseases into the clinic this year. The funding round was led by The Column Group and had participation from Alexandria Ventures and NEVA SGR. Tr1X will be led by CEO William Lis, who has been in biotech for over 25 years and was the interim CEO of Jasper Therape

Pictured: Money growth/iStock, RomoloTavani The investment in Illinois-based Cour Pharmaceuticals had participation from Bristol Myers Squibb, Pfizer Breakthrough Growth Initiatives and Roche Ventures. Pictured: Plants wrapped in dollar bills grow in ground/iStock, RomoloTavani Illinois-based Cour Pharmaceuticals on Tuesday announced that it raised $105 million in Series A funding to help the company advance multiple, wholly-owned candidates. The investment was led by Lumira Ventures and